A157 THE THRESHOLD FOR INFLIXIMAB TROUGH LEVELS LEADING TO DOSE ESCALATION DIFFERS BETWEEN CROHN’S DISEASE AND ULCERATIVE COLITIS

摘要

BackgroundTherapeutic drug monitoring (TDM) of infliximab (IFX) provides an objective measure that allows physicians to optimize the dose for patients on biologic therapies and potentially reduce loss of response (LOR). The currently accepted therapeutic range is 3 – 7 μg/mL. With the potential for LOR with low drug levels and the high cost of IFX, it is important to manage medications efficiently. To better understand how physicians at the University of Alberta Hospital are using TDM, we conducted a retrospective chart review to see the clinical decisions made in response to TDM. Major clinical decisions include: no change, dose escalate (increase in dose or shorten interval), reload (2 extra doses 2 weeks apart), or dose de-escalate (decrease in dose or lengthen interval).